We compared the efficacy of single agents, vemurafenib or trametinib, to that of the combination of vemurafenib plus trametinib in BRAF mutated NSCLC cell lines, HCC364 [V600E-BRAF, WT EGFR] and H1755 [non-V600E, G469A BRAF mutant, WT EGFR]. Here, EGFR is linked to non-small cell lung carcinoma.